ROS1 rearrangements represent a rare but clinically significant oncogenic driver in non-small cell lung carcinoma (NSCLC), occurring in approximately 1–2% of cases. While crizotinib and entrectinib are established targeted therapies, limitations such as central nervous system (CNS) progression and acquired resistance underscore the need for next-generation inhibitors. Taletrectinib, a highly selective ROS1 tyrosine kinase inhibitor, has shown promising activity in both TKI-naïve and pretreated patients, including those with CNS metastases and resistance mutations like G2032R. Early-phase clinical trials report encouraging objective response rates with a manageable safety profile, distinguishing taletrectinib as a potential best-in-class therapy. Its favorable pharmacokinetics and brain penetration may address key gaps left by earlier ROS1 inhibitors, particularly for patients with intracranial disease progression. Given the unmet clinical need, taletrectinib represents an important advancement in precision oncology for ROS1-positive NSCLC. Ongoing phase II and III studies will be crucial in validating its efficacy and positioning within treatment algorithms. Integration of taletrectinib into clinical practice has the potential to improve survival outcomes and quality of life in this molecularly defined subset of NSCLC patients.
SAEED et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: